• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides compounds of the formula (I) <CHEM> wherein R<6> is chlorine, bromine, iodine, C1-4 alkyl or trifluoromethyl; R<7> is hydrogen, halogen, C1-4 alkyl or trifluoromethyl or R<6> and R<7> form a -CH=CH-CH=CH- group optionally substituted by a halogen atom or a C1-4 alkyl or trifluoromethyl group; R<8> is hydrogen, halogen, C1-4 alkyl or trifluoromethyl; R<9> is hydrogen, halogen, C1-4 alkyl or trifluoromethyl, and R<1><0> is hydrogen, methyl or fluorine, provided that at most only two of R<7>-R<1><0> are other than hydrogen and that R<7>-R<1><0> are not all hydrogen when R<6> is chlorine, which are useful as intermediates for the preparation of compounds of formula (II) <CHEM> wherein R<6>, R<7>, R<8>, R<9> and R<1><0> are as defined in claim 1 and R<1><1> is amino, C1-4 acylamino or di-substituted aminomethyleneamino, being useful in the treatment of CNS disorders such epilepsy.
    公开号:SU1055331A3
    申请号:SU802932704
    申请日:1980-06-02
    公开日:1983-11-15
    发明作者:Джордж Бакстер Мартин；Реджинальд-Элфик Альберт；Айнсли Миллер Алистэр
    申请人:Дзе Велкам Фаундейшн Лимитед (Фирма)；
    IPC主号:
    专利说明:

    31055 After cooling, the solution is evaporated in vacuo and distilled under a nitrogen atmosphere. The yield of 35.5 g (85), tk.npUb8 ° C (300 mm Hg St), 2,3 Dichlorobenzoyl cyanide. 5 A mixture of monovalent copper cyanide (Pb, 9 g, 0.1 M), potassium iodide (68.5 g, 0, it1 M) and xylene (00 ml) is boiled under nitrogen with a Dean-Stark trap for 2 h to complete 10 water separation,. Solution 2. -dichlorobenzoyl chloride (g, 0.17 M) in metal-dried xylene (130 ml) was added dropwise to the prepared mixture of dry copper cyanide and xylene. The resulting mixture was stirred and heated to boiling point, and then boiled for 72 hours. The cooled mixture was filtered and the solid was thoroughly washed with dry xylene (200 ml of "The filtrate and the washing solutions were combined and evaporated in an vacuum, an oil was obtained. Yield 32 g (E. 25 3,5-Diamino-6-2.3 dichlorophenyl) -1.21, -triazine A solution of 2,3-dichlorobenzoyl cyanide (32 g, 0.16 M) in dimethyl sulfoxide (80 ml) is added drop by drop into a mixed, aminoguanidine bicarbonate suspension (81, 6 g, .0.6 M), which is pretreated with a 8N solution of nitrogen Acidic acid (00 ml | approx. The mixture is stirred for 3 hours, then kept at room temperature for 7 days “The cooled mixture is alkalized with 0.88N aqueous solution of ammonia ml) while stirring, then stirred under ice cooling for 30 minutes. minutes, filtered and the solid obtained is thoroughly pressed with water and dried, in vacuum (this substance is added to a 10% solution of potassium hydroxide in methanol (SHO ml)); and boil for 1.5 hours. After cooling, the solution is evaporated in vacuo, treated with ice water (BOO ml), then stirred for 30 minutes and filtered. The residue from the SO filter is dried and recrystallized from isopropanol, 3.5 diamino-6- (2,3-dichlorophenyl) -1,2,4-triazine are obtained. Yield 6.8 g (15.6%), t, mp; 21b-218 ° C. Example 2 Analogously to Example 1, the compounds shown in Table 1 are obtained. 1 and 2, 1 Table 1 Table2 Example 3. Preparation of 3,3-Diamino-6- (2,3,5-trichlorophenyl) -1,2, triazine i, 2,3,2-Trichlorobenzoic acid. Powdered sodium nitrite (37 g. 0.5 M) is added in portions to concentrated sulfuric acid (270 ml) with stirring under a nitrogen atmosphere at a temperature not higher. 3-amino -2,5-Dichlorobenzoic acid (100 g, 0.5 M) is dissolved in hot glacial acetic acid (1200 ml), the resulting solution is rapidly cooled to room temperature and added dropwise to the aforementioned stirred cooled mixture of nitric acid so that the temperature inside the mixture does not rise above. The solution formed after the addition is kept at room temperature for 2 hours, then it is slowly added to the stirred chloride solution one of copper (97.0 g, 0.97 M) in concentrated hydrochloric acid (970 ml). The resulting mixture stir until the nitrogen separation ceases, and then incubate overnight. The solid is separated by filtration, washed with water and dried in vacuo. Output 90.1 g (VE%), so pl. l6t-l65 ° C, 2,3,5-Trichlorobenzoyl chloride. A mixture of 2,3,5 trichlorobenzoic acid (90.0 g, 0, M) and dimethyl formamide, (1 ml) v.thionyl chloride (200 ml) is heated to the boiling point and boiled for 2 hours. The cooled solution is evaporated in a vacuum, the residue is distilled under nitrogen. Exit 89.2. g (90), Tokipo 158-1bO ° C; . (30 mm of RT „STe) about 2, 3 I З-Grikhlorbenzoiltsiani /. A mixture of monovalent copper cyanide (89 g, 0.9 M), potassium iodide (150.5 g 0.9 M; and xylene (800 ml) is boiled under nitrogen using a Dean-Stark trap for 2 y A solution of 2, 3,5-trichlorobenzoyl chloride (89 g, O, 3B M) in dried sodium M xylene (100 ml) is added to the above suspension. The mixture is stirred and boiled for 72 hours. The cooled mixture is filtered and the solid is thoroughly washed with dried sodium xylene (200 ml). The filtrate and washing solutions are combined and evaporated in vacuo to give an oil. 76 g yield (9b). 3,5-Diamino-6- (2,3,5-trih srphenyl) -1,2, triazine. A solution of 2,35-trichlorobenzoyl cyanide (38.5 g, 0.16 M) in dimethyl sulfoxide (80 ml) is added dropwise to a stirred suspension of aminoguanidine bicarbonate (b5.7b g, 0.32 M which is pretreated with an 8N aqueous solution of nitric acid (5 BO ml). The mixture is stirred for 3 hours and then kept at room temperature for 21 hours. The solid is separated by filtration, washed with water (2 X 100 ml) and dried in a vacuum. The suspension of the dried solid in a 10 | solution of potassium hydrate in methanol (320 ml) is boiled for 1 h, cm Referring vayut cooled and evaporated in vacuo The residue was treated with ice-water (2PO ml), the resulting solid was separated by filtration and dried in vacuo. This product is purified on a silica gel column (25 mm diameter, 200 g MFC silica gel) using ethyl acetate / methanol / acetic acid (90: 2.5: 2.5) as eluent. Fractions 50 to 80 (900 drops per fraction) are collected, combined and evaporated in vacuo. The resulting solid is recrystallized from isopropanol to obtain 3,5-diamino-6- (2,3,5-trichlorophenyl) -1,2, -4-triazine. Yield 0.77 g (1j6), m.p., 232-235 ° C, P. p and M er, Preparation of 5-acetamido-3-amino-6- (I, 3-dichlorophenyl) -1, 2, A-triazine, A solution of 3,5 diamino-6- (2,3-dichlorophenyl) -1,2, -triazine (2 g, 8 mmol) and acetic anhydride (10 ml) in acetic acid (20 ml) is stirred and boiled t 2 h “The solution is then cooled and evaporated in vacuo. The residue is treated with an aqueous solution .1. 0.88) (ammonia I (100 ml) and the resulting mixture was stirred for 2 hours. The solid was separated by filtration, dried, then recrystallized from isopropanol to obtain 5-acetamido-3-amino-6- (2,3-Dichlorophenyl A) -1,2,4-triazino. Yield 1.0 g (2), mp 250252®C, Example 5o Preparation of 3-amino-6- (2 5 3-Dichlorophenyl) -5-Dimethylaminomethylene-amino-1, 2, triazine oxalate. Dimethyl acetal dimethylformamide (1 ml) was added dropwise to a stirred mixture of 3,5-diamino-6- (2,3-dichlorophenyl) -1,2, -triazine (1 g, A mM) in dry dimethylformamide (20 ml) under nitrogen atmosphere. The mixture is stirred and heated. The resulting solution is cooled and evaporated in vacuo at 2 hours. The resulting oil is washed with water (20 ml), then dissolved in a solution of oxalic acid (1 g) in methanol (20 ml). When ether is added (100 ml) an oil is obtained which slowly crystallizes. The crystalline mass obtained is recrystallized from aqueous isopropanol to give 3-amino-6- (2,3-dichlorophenyl) -5-dimethylaminomethylene-amino-1, 2,4-triazine oxalate. Output 0.19 g (1U), t, pl „172-175 ° C (times.), Example 6, Preparation of 2.3 dichlorophenyl-2- (guanidinylimino) -acetonitrile. . .
    Concentrated sulfuric acid (300 ml) is added to water (300 ml), cooled to 20 ° C. Aminoguanidine bicarbonate (60 g, 0, mol) is added followed by a solution of 2,3-dichlorobenzoyl cyanide (50 g, 0.25 mol). ) in acetonitrile (200 ml) ,. The mixture is stirred at room temperature for 3 days, then scaled with 10 by adding concentrated ammonia solution (750 ml) at 10-20 ° C (with cooling). After stirring for the next 20 minutes, the solid is filtered, washed with water (1500 ml ) at
    15, then dried at 50 ° C in yakum, a yellow solid is obtained; short, 7 g (68), so pl. 172-r73 CJ.
    II p and mer 7 Preparation of 3,5-Diamino-6- (2,3 Dichlorophenyl) -1,2,4-tri20 azine,
    L. A mixture of 2,3-dichlorophenyl-2- (guanidinylimino) acetonitrile (g, 0.02 mol), N. propanol (C6 ml) and activated carbon (1.0 g) is stirred, boiled under reflux in a for 1.5 hours. The hot solution is filtered, left to stand at overnight, the product is filtered, then dried at 1.
    30/5 mm pTaSTo, get a white solid 2.8 g (5b), t, mp, 216 218 ° C.
    In a solution of 2.3 Dichlorophenyl-2-. - (guaiidinylimino) acetonitrile (5.0 g,
    35 0.02 mol) in a mixture of n, propanol (30 ml) and water (7.5 ml) is stirred and refluxed for 8 hours. Activated carbon (1.2 g) is added, and after over 40 stirring for an additional 5 minutes, the hot solution is filtered and left to stand for 3 hours. The T1p6duct is filtered off and recrystallized from a mixture of n-propanol (20 ml) and water (5 ml). The solid is filtered and dried at mm Hg. one hundred, get a white solid 2.6 g (52), TopPl "21b-218So
    C. Concentrated sulfuric acid (600 ml) is added to water (600 ml) and the solution is cooled to 20 ° C. Aminoguanidine bicarbonate (120 g, 0.88 mol) is added to the solution, followed by the addition of a solution of 2,3 Dichlorobenzo-55 ylcyanide ( 100.0 g, 0.5 mol) in acetonitrile (00 ml) o After stirring at room temperature for. For 3 days, the reaction mixture was alkalified by adding a concentrated solution of ammonia (1500 ml) at 10-20 ° C, refluxed with stirring for 2.5 hours, and the solvent was removed by distillation up to a distillate temperature of 85 ° C. After stirring overnight, the solid is filtered off, washed with water (500 ml) at 80 ° C and dried at .80 ° C in vacuum, to obtain a crude product (103.6 g, 8P),
    The substance is crystallized from n „propanol, and then the pure product is obtained from methanol with mp, 216-218 C (37.5 g, 29%).
    The pharmacological activity of the compounds obtained by the proposed method is presented in Table. 3, J and 5o
    Table 3 91055 Table, Epg ,, mice., G / kg H2.95 2-Ye16.5, 3-СГ6.5-г - Table З,.,. 1, Ж RR Mice of the Rat 11-, 1 i3-Clj NN7 250 6AO 2,5-SC NHj. 708 640 3110 Anti-convulsive activity was determined using standard maximum current test. Indicators of Sh5o (expressed in mg / kg 5 of 3,5-diamino-6- (2 „3-dichlorophenyl) -1,2, triazine and 3,5-diamino-6- (2,5-dichlr Phenyl) -, 2-triazine is determined in mice and rats. The loso is determined at a dose at which 50% of the animals survive for 10 days after use of the compound.
    权利要求:
    Claims (2)
    [1]
    1. The method of obtaining derivatives. 3,5 “diamino ·! , 2,4-triazine of general formula • n g u (~ 5- (I) Ν = Ν Μ * wherein R * - chloro, bromo, iodo, methyl or trifluoromethyl}.
    R ^ is hydrogen or chlorine, or R 1 and R 2 together form the group —CH = CH — CH = CH ~;
    R ^ is hydrogen or bromine;
    R 4 is hydrogen, chlorine or bromine;
    R - hydrogen, methyl or fluorine; R 6 is an amino, acetylamino or (dimethylaminomethylene amino group, provided that no more than two substituents from the number R 2 rR s are different from hydrogen and that not all substituents from the number R ^ -R 5 are hydrogen if R1 is chlorine, or their acid addition salts, wherein the compound of general formula
    C = S-W-C where R1 and R z have the indicated meanings, are heated at 50-100 ° C in an inert solvent in which the reagents are soluble, followed by isolation of the whole product in the form of a base or an acid addition salt, or by acylation for obtaining compound I, where R® is an acetylamino group, or dimethylaminomethylation to obtain compound J, where R® is dimethyl. aminomethyleneamino group; and isolating the desired product in the form of a base or an acid addition salt.
    [2]
    2. The method according to π. 1, with the fact that the process is carried out in the presence of a base in a C ^ -C ^ -al- • canola.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1055331A3|1983-11-15|Process for preparing derivatives of 3,5-diamino-1,2,4-triazine or their acid addition salts
    RU2017736C1|1994-08-15|5,6-dihydro-2-|-1,2,4-triazine-3,5-|-diones showing anticoxidial and coxidiostatic activity
    US5166358A|1992-11-24|Process for 1-phenyl-imidazoline-2,5-diones
    US4118561A|1978-10-03|7-|-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
    SU433681A3|1974-06-25|METHOD OF OBTAINING 1,2.4 ^ TRIAZIN-5-ONOV
    RU2335497C2|2008-10-10|Method of obtaining 3,5-diamino-6-|-1,2,4-triazine of high purity grade
    EP0035708B1|1983-10-12|Process for the preparation of 4-amino-6-tert.-butyl-3-methylthio-1,2,4-triazin-5|-one
    FI64155B|1983-06-30|NYTT FOERFARANDE FOER FRAMSTAELLNING AV 5-AMINO-1,2,3-TIADIAZOL
    IL116384A|1996-10-16|Ylidene compounds and their preparation
    US6329521B2|2001-12-11|Process for preparing substituted benzoyl cyanide amidinohydrazones
    CA1268463A|1990-05-01|Preparation of substituted and unsubstituted 2-[|-carbamoyl]-3-quinolinecarboxylic, nicotinic and benzoic acids
    EP0253396B1|1993-03-17|Process for preparing 5,6-substituted-2,4-quinazolinediamines and intermediates
    JP2019507156A|2019-03-14|Process for producing 4-alkoxy-3-hydroxypicolinic acid
    EP0181145A2|1986-05-14|Heterocyclic compounds
    CA1251205A|1989-03-14|Derivatives of dihydroindenothiadiazinone
    US4521616A|1985-06-04|Method for the preparation of fluoroanthranilic acids
    JPH05246985A|1993-09-24|Method for preparation of bismaleinimide derivative
    CA1158668A|1983-12-13|PROCESS FOR THE PREPARATION OF .alpha.-KETOCARBOXYLICACID N-ACYLAMIDES
    GB1571742A|1980-07-16|Process for the preparation of isoindolinone derivatives
    KR890002425B1|1989-07-03|Process for synthesis of 1-|-3-methyl-4-difluoromethyl-2-1,2,4-triazoline)-5-one derivative
    US4772747A|1988-09-20|Preparation of 2,4,6-trichlorophenylhydrazine
    RU2231526C2|2004-06-27|Method for preparing 3,5-diamino-6-|-1,2,4-triazine
    SARGENT1954|THE SYNTHESIS OF 1-ETHYL-, 2-ETHYL-, 3-ETHYL-AND 4-ETHYL-ACRIDINE1
    US4581177A|1986-04-08|Process for the preparation of 3-cyano-4-aminoacetophenones
    BE817776Q|1975-01-17|-Phenyl tetrazine derivs. and their diuretics and saluretics
    同族专利:
    公开号 | 公开日
    PL124029B1|1982-12-31|
    FI67844B|1985-02-28|
    DK153787B|1988-09-05|
    YU145680A|1983-02-28|
    DD151309A5|1981-10-14|
    EP0021121B1|1983-05-11|
    DK233880A|1980-12-02|
    AR227521A1|1982-11-15|
    ES491998A0|1981-05-16|
    NL950007I1|1995-06-16|
    IT1147087B|1986-11-19|
    IL60201A|1984-05-31|
    JPS6133163A|1986-02-17|
    NL950007I2|1997-02-03|
    CZ384891A3|1993-10-13|
    PL224633A1|1981-02-13|
    BG60427B2|1995-03-31|
    FI67844C|1985-06-10|
    EP0021121A1|1981-01-07|
    UA5576A1|1994-12-28|
    US4486354A|1984-12-04|
    JPH0144179B2|1989-09-26|
    AU530999B2|1983-08-04|
    AT370097B|1983-02-25|
    EP0059987A1|1982-09-15|
    IL60201D0|1980-07-31|
    HU182086B|1983-12-28|
    EP0059987B1|1985-08-14|
    IE801126L|1980-12-01|
    JPS5625169A|1981-03-10|
    ZA803250B|1982-01-27|
    US4602017A|1986-07-22|
    ATA289680A|1982-07-15|
    IE49823B1|1985-12-25|
    MY8500062A|1985-12-31|
    FI801758A|1980-12-02|
    DK153787C|1989-01-16|
    CA1112643A|1981-11-17|
    ES8104993A1|1981-05-16|
    AU5890680A|1980-12-04|
    ZW12980A1|1982-01-06|
    MX9202962A|1992-07-01|
    CS234018B2|1985-03-14|
    GR68380B|1981-12-28|
    IT8048848D0|1980-05-30|
    NZ193890A|1984-07-06|
    AU566870B2|1987-11-05|
    JPH0144706B2|1989-09-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB759014A|1952-02-26|1956-10-10|Wellcome Found|Improvements in triazines and their manufacture|
    AT190941B|1954-09-22|1957-07-25|Chemie Linz Ag|Process for the production of new guanylhydrazones|
    US2952677A|1956-10-01|1960-09-13|Ici Ltd|Aminoguanadine compounds|
    BE663481A|1964-05-05|
    DE1802364C3|1967-10-12|1975-03-20|Shell Internationale Research Maatschappij B.V., Den Haag |Medicines with a thyme- tic effect|
    GB1223492A|1967-10-13|1971-02-24|American Home Prod|Guanidines|
    US3637688A|1970-01-09|1972-01-25|American Home Prod|6--3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines|
    EP0086502B1|1979-08-16|1987-03-25|The Wellcome Foundation Limited|Substituted aromatic triazines|EP0086502B1|1979-08-16|1987-03-25|The Wellcome Foundation Limited|Substituted aromatic triazines|
    GB8328757D0|1983-10-27|1983-11-30|Wellcome Found|Chemical compounds|
    DE3600891A1|1986-01-15|1987-07-16|Bayer Ag|1,8-BRIDGED 4-CHINOLON-3-CARBONIC ACIDS AND MEDICINAL PRODUCTS CONTAINING THEM|
    GB8613183D0|1986-05-30|1986-07-02|Wellcome Found|Triazine salt|
    US4972496A|1986-07-25|1990-11-20|Grid Systems Corporation|Handwritten keyboardless entry computer system|
    FI895821A0|1988-12-07|1989-12-05|Wellcome Found|PHARMACEUTICAL ACTIVE CNS FOERENINGAR.|
    US5136080A|1989-12-04|1992-08-04|Burroughs Wellcome Co.|Nitrile compounds|
    GB9012312D0|1990-06-01|1990-07-18|Wellcome Found|Pharmacologically active cns compounds|
    GB9012311D0|1990-06-01|1990-07-18|Wellcome Found|Pharmacologically active cns compounds|
    DE69207656T2|1991-01-30|1996-10-17|Wellcome Found|WATER-SOLUBLE TABLETS|
    US5629016A|1991-01-30|1997-05-13|Glaxo Wellcome Inc.|Water-dispersible tablets|
    US5698226A|1993-07-13|1997-12-16|Glaxo Wellcome Inc.|Water-dispersible tablets|
    GB9124807D0|1991-11-22|1992-01-15|Wellcome Found|Pharmaceutical formulations|
    GB9203483D0|1992-02-19|1992-04-08|Wellcome Found|Anti-inflammatory compounds|
    WO1993025207A1|1992-06-12|1993-12-23|The Wellcome Foundation Limited|Use of 3,5-diamino-6--1,2,4-triazine isethionate for the treatment and prevention of dependence, tolerance and sensitization of drugs|
    GB9215908D0|1992-07-27|1992-09-09|Wellcome Found|Water dispersible tablets|
    FR2699077B1|1992-12-16|1995-01-13|Rhone Poulenc Rorer Sa|Application of anticonvulsants in the treatment of neurological lesions linked to trauma.|
    US6133299A|1993-02-25|2000-10-17|Warner-Lambert Company|Methods for treating neurodegenerative diseases and disorders using N--N'-pyridinyl ureas and other anticonvulsant compounds|
    US5866597A|1993-03-19|1999-02-02|Glaxo Wellcome Inc.|Use of triazine compounds for the treatment of memory and learning disorders|
    GB9305692D0|1993-03-19|1993-05-05|Wellcome Found|Therapeutic triazine compounds and use|
    GB9305693D0|1993-03-19|1993-05-05|Wellcome Found|Therapeutic triazine compounds and use|
    GB9317146D0|1993-08-18|1993-10-06|Wellcome Found|Therapeutic combinations|
    GB9424766D0|1994-12-07|1995-02-08|Wellcome Found|Pharmaceutical composition|
    HU224688B1|1994-12-30|2005-12-28|The Wellcome Foundation Limited|Process for the preparation of 3,5-diamino-6--1,2,4-triazine |
    GB9426448D0|1994-12-30|1995-03-01|Wellcome Found|Process|
    GB9512854D0|1995-06-23|1995-08-23|Wellcome Found|Novel formulation|
    GB9518027D0|1995-09-05|1995-11-08|Wellcome Found|Pharmacologically active compound|
    FR2741879A1|1995-12-05|1997-06-06|Esteve Labor Dr|FLUOROPHENYL-TRIAZINE AND PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS|
    US6202491B1|1997-07-22|2001-03-20|Skf Condition Monitoring, Inc.|Digital vibration coupling stud|
    GB9726987D0|1997-12-22|1998-02-18|Glaxo Group Ltd|Compounds|
    US6124500A|1998-03-09|2000-09-26|Rohm And Haas Company|Process for synthesizing benzoic acids|
    US20020055177A1|1999-03-10|2002-05-09|Glaxo Wellcome Inc.|Compound and its use|
    GB9812413D0|1998-06-10|1998-08-05|Glaxo Group Ltd|Compound and its use|
    EP1140872B1|1998-12-14|2003-09-17|Torrent Pharmaceuticals Ltd|An improved process for the preparation of 3,5-diamino-6--1,2,4-triazine|
    JP4625637B2|2002-02-22|2011-02-02|シャイアエルエルシー|Active substance delivery system and method for protecting and administering an active substance|
    GB9907965D0|1999-04-09|1999-06-02|Glaxo Group Ltd|Medical use|
    WO2000061188A1|1999-04-09|2000-10-19|Euro-Celtique S.A.|Sodium channel blocker compositions and the use thereof|
    DE10085384B4|2000-01-03|2006-06-14|Rpg Life Sciences Limited|Preparation of 6--1,2,4-triazine-3,5-diamine , useful for treating epilepsy, starting from 2,3-dichloronitrobenzene|
    IL134730A|2000-02-25|2003-10-31|Chemagis Ltd|Process for preparing substituted benzoyl cyanide amidinohydrazones|
    IL155704D0|2000-11-30|2003-11-23|Pfizer Prod Inc|Combination of gaba agonists and sorbitol dehydrogenase inhibitors|
    SK6092003A3|2000-11-30|2004-07-07|Pfizer Prod Inc|Combination of GABA agonists and aldosereductase inhibitors|
    JP2004526714A|2001-02-27|2004-09-02|テバファーマシューティカルインダストリーズリミティド|New crystalline forms of lamotrigine and methods for their preparation|
    PT1423168E|2001-09-03|2006-05-31|Newron Pharm Spa|PHARMACEUTICAL COMPOSITION WHICH UNDERSTAND GABAPENTINE OR ITS ANALOGUE AND AN X-AMINOAMIDE AND ITS USE AS ANALGESIC|
    CA2366521C|2001-12-24|2007-03-06|Brantford Chemicals Inc.|A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines|
    CA2483103A1|2002-04-23|2003-11-06|Teva Pharmaceutical Industries Ltd.|Pharmaceutical composition containing lamotrigine particles of defined morphology|
    US8637512B2|2002-07-29|2014-01-28|Glaxo Group Limited|Formulations and method of treatment|
    HU225667B1|2002-09-20|2007-05-29|Richter Gedeon Nyrt|Method for producing high-purity 3,5-diamino-6--1,2,4-triazine|
    ES2209639B1|2002-10-31|2005-08-01|Vita Cientifica, S.L.|PROCEDURE FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND AND OBTAINING YOUR INTERMEDIATE.|
    WO2004083191A1|2003-03-17|2004-09-30|Hetero Drugs Limited|Novel crystalline forms of lamotrigine|
    WO2004085426A1|2003-03-27|2004-10-07|Hetero Drugs Limited|Novel crystalline forms of candesartan cilexetil|
    EP1633400A2|2003-05-16|2006-03-15|Pfizer Products Inc.|Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines|
    WO2004103340A1|2003-05-20|2004-12-02|Ranbaxy Laboratories Limited|Water dispersible tablets of lamotrigine|
    GB2395483A|2003-07-03|2004-05-26|Jubilant Organosys Ltd|Crystalline lamotrigine and its monohydrate|
    AU2004305563C1|2003-12-11|2011-07-07|Sunovion Pharmaceuticals Inc.|Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression|
    WO2005082372A1|2004-01-29|2005-09-09|Pfizer Products Inc.|COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS|
    EP1737473A4|2004-04-19|2009-08-26|Noven Therapeutics Llc|Lithium combinations, and uses related thereto|
    SI1809271T1|2004-09-10|2010-10-29|Newron Pharm Spa|Use of - benzylamino-propanamides as sodium and/or calcium channel selective modulators|
    AU2006295121B2|2005-09-23|2011-10-27|Janssen Pharmaceutica, N.V.|Hexahydro-cycloheptapyrazole cannabinoid modulators|
    US7825151B2|2005-09-23|2010-11-02|Janssen Pharmaceutica Nv|Hexahydro-cyclooctyl pyrazole cannabinoid modulators|
    US8378117B2|2005-09-23|2013-02-19|Janssen Pharmaceutica N.V.|Hexahydro-cycloheptapyrazole cannabinoid modulators|
    BRPI0616401A2|2005-09-23|2011-06-21|Janssen Pharmaceutica Nv|cannabinoid hexahydro-cycloothyl pyrazole modulators and their use|
    EP1937646A1|2005-09-23|2008-07-02|Janssen Pharmaceutica N.V.|Tetrahydro-cyclopentyl pyrazole cannabinoid modulators|
    US8378096B2|2005-09-23|2013-02-19|Janssen Pharmaceutica N.V.|Hexahydro-cycloheptapyrazole cannabinoid modulators|
    US20070117858A1|2005-11-23|2007-05-24|Mingde Xia|Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators|
    US7526911B2|2006-02-03|2009-05-05|Rolls-Royce Corporation|Gas turbine engine fuel system with fuel metering valve|
    US7795294B2|2006-02-14|2010-09-14|Janssen Pharmaceutica N.V.|Tetrahydro-2H-indazole pyrazole cannabinoid modulators|
    US20070254911A1|2006-03-27|2007-11-01|Mingde Xia|Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators|
    US8012957B2|2006-03-27|2011-09-06|Janssen Pharmaceutica Nv|Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators|
    WO2007122638A2|2006-04-26|2007-11-01|Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd.|An improved process for preparation of lamotrigine intermediates|
    AT452125T|2006-05-31|2010-01-15|Calaire Chimie Sas|PROCESS FOR THE PREPARATION OF LAMOTRIGIN AND ITS INTERMEDIATE 2,3-DICHLORBENZOYL CHLORIDE|
    GB0613836D0|2006-07-13|2006-08-23|Univ Greenwich|New medical use of triazine derivatives|
    US20120142919A1|2006-08-02|2012-06-07|Medichem, S.A.|Method for synthesizing lamotrigine|
    WO2008019798A1|2006-08-14|2008-02-21|Lonza Ag|A process for the preparation of lamotrigine|
    JP2010516731A|2007-01-24|2010-05-20|グラクソグループリミテッド|Pharmaceutical composition comprising 2-methoxy-5--benzyl]- -amine|
    US7943653B2|2007-08-13|2011-05-17|Janssen Pharmaceutica N.V.|Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators|
    US20090076010A1|2007-09-13|2009-03-19|Protia, Llc|Deuterium-enriched lamotrigine|
    WO2009061513A1|2007-11-09|2009-05-14|Thar Pharmaceuticals|Crystalline forms of lamotrigine|
    GB0800741D0|2008-01-16|2008-02-20|Univ Greenwich|Cyclic triazo and diazo sodium channel blockers|
    US20100190752A1|2008-09-05|2010-07-29|Gruenenthal Gmbh|Pharmaceutical Combination|
    CA2760219C|2009-05-13|2016-08-16|Nektar Therapeutics|Oligomer-containing substituted aromatic triazine compounds|
    EP2564836A1|2009-05-20|2013-03-06|Ranbaxy Laboratories Limited|Controlled release lamotrigine formulations|
    GB2471729A|2009-07-08|2011-01-12|Univ Greenwich|1,2,4-triazine derivatives and their use as sodium channel blockers|
    GB2471713A|2009-07-08|2011-01-12|Univ Greenwich|1,2,4-triazine derivatives and their use as sodium channel blockers|
    US20110052686A1|2009-09-03|2011-03-03|Ranbaxy Laboratories Limited|Modified release lamotrigine tablets|
    GB201111712D0|2011-07-08|2011-08-24|Gosforth Ct Holdings Pty Ltd|Pharmaceutical compositions|
    WO2013183985A1|2012-06-05|2013-12-12|Erasmus University Medical Center Rotterdam|Method of treating cognitive impairment and compounds for use therein|
    WO2015092819A2|2013-12-21|2015-06-25|Nektar TherapeuticsPvt. Ltd.|Derivatives of 6--1,2,4-triazin-5- amine|
    CN107921046A|2015-06-12|2018-04-17|格林威治大学|Pyrrolotriazine derivatives as interferon Γ inhibitor|
    KR20210065206A|2016-12-16|2021-06-03|이도르시아 파마슈티컬스 리미티드|Pharmaceutical combination comprising a t-type calcium channel blocker|
    TW202023547A|2018-09-21|2020-07-01|南韓愛思開生物製藥股份有限公司|Compound having oxadiazole and pharmaceutical composition containing the same|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB7919257|1979-06-01|LV920339A| LV5246A3|1979-06-01|1992-12-18|Saturation of 3,5-diamino-1,2,4-triazine or its additive additive|
    LTRP273A| LT2066B|1979-06-01|1992-12-30|BACKGROUND OF THE INVENTION OF 3,5-DIAMINO-1,2,4-TRIAZINE OR SULFUR|
    [返回顶部]